CA2758847A1 - Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound - Google Patents

Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Download PDF

Info

Publication number
CA2758847A1
CA2758847A1 CA2758847A CA2758847A CA2758847A1 CA 2758847 A1 CA2758847 A1 CA 2758847A1 CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A1 CA2758847 A1 CA 2758847A1
Authority
CA
Canada
Prior art keywords
capsule
peg
tpgs
pharmaceutical composition
crystallization inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758847A
Other languages
English (en)
French (fr)
Inventor
Sachin Chandran
Rajesh Babulal Gandhi
Jaquan Kalani Levons
Robert Kevin Perrone
Christopher P. Price
Krishnaswamy Srinivas Raghavan
Ismat Ullah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2758847A1 publication Critical patent/CA2758847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2758847A 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Abandoned CA2758847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169,061 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
CA2758847A1 true CA2758847A1 (en) 2010-10-21

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758847A Abandoned CA2758847A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Country Status (14)

Country Link
US (1) US8252821B2 (enExample)
EP (1) EP2419090B1 (enExample)
JP (1) JP2012524092A (enExample)
KR (1) KR20120022766A (enExample)
CN (1) CN102395361A (enExample)
AR (1) AR076305A1 (enExample)
AU (1) AU2010236602A1 (enExample)
BR (1) BRPI1015483A2 (enExample)
CA (1) CA2758847A1 (enExample)
EA (1) EA201101286A1 (enExample)
MX (1) MX2011010514A (enExample)
NZ (1) NZ595335A (enExample)
TW (1) TW201041609A (enExample)
WO (1) WO2010120755A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
CN102577156B (zh) 2009-10-02 2016-01-20 Lg电子株式会社 用于下行链路参考信号的发送方法和装置
CN103402543B (zh) * 2010-12-16 2015-09-16 德克萨斯州立大学董事会 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
AU2012250050B2 (en) 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3927324A1 (en) * 2019-02-22 2021-12-29 Janssen Pharmaceutica NV Pharmaceutical formulations
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4199911A1 (en) * 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
ATE280152T1 (de) 1999-01-27 2004-11-15 Wyeth Corp Acetylenische sulfonamid-thiol-tace-inhibitoren
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
EP1680406A1 (en) 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
AU2005237580B2 (en) * 2004-04-28 2011-06-16 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
BRPI0519036A2 (pt) * 2004-12-14 2008-12-23 Wyeth Corp mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US20110059940A1 (en) 2008-05-08 2011-03-10 Bristol- Myers Squibb Company 2-Aryl Glycinamide Derivatives
JP2012520875A (ja) 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−（ｎ−スルホンアミド）アセトアミド化合物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
NZ595335A (en) 2013-03-28
AU2010236602A1 (en) 2011-10-13
BRPI1015483A2 (pt) 2016-04-26
KR20120022766A (ko) 2012-03-12
MX2011010514A (es) 2011-11-29
EA201101286A1 (ru) 2012-04-30
US8252821B2 (en) 2012-08-28
US20100260837A1 (en) 2010-10-14
CN102395361A (zh) 2012-03-28
JP2012524092A (ja) 2012-10-11
WO2010120755A1 (en) 2010-10-21
EP2419090B1 (en) 2013-02-13
TW201041609A (en) 2010-12-01
AR076305A1 (es) 2011-06-01
EP2419090A1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
US8252821B2 (en) Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011273519B2 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate
ES2641637T3 (es) Composiciones farmacéuticas que comprenden ligandos del receptor sigma
ES2935792T3 (es) Formas farmacéuticas orales de bendamustina y uso terapéutico de las mismas
PL209704B1 (pl) Kompozycja farmaceutyczna w postaci tabletki do sporządzania zawiesin oraz sposób wytwarzania tabletki do sporządzania zawiesin zawierającej 40-O-(2-hydroksy)etylo-rapamycynę
JP5749247B2 (ja) 経口用徐放性固形製剤
JPWO2008129846A1 (ja) 医薬組成物
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
CN110292575B (zh) 药物组合物
JP2011500548A (ja) マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
JPWO2010147169A1 (ja) 溶出性の改善された医薬組成物
EP2419086B1 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
JP6093762B2 (ja) 徐放性製剤
US20260069569A1 (en) Ebselen containing oral dosage forms
US20250352482A1 (en) Amorphous dosage form containing ebselen
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
KR20240173178A (ko) 안정성 및 용출률이 개선된 크리스데살라진 함유 약학 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413